We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
MDRNA, Inc. Reports Positive Results for its Proprietary siRNA Delivery Technology
News

MDRNA, Inc. Reports Positive Results for its Proprietary siRNA Delivery Technology

MDRNA, Inc. Reports Positive Results for its Proprietary siRNA Delivery Technology
News

MDRNA, Inc. Reports Positive Results for its Proprietary siRNA Delivery Technology

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "MDRNA, Inc. Reports Positive Results for its Proprietary siRNA Delivery Technology"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

MDRNA, Inc. has announced that its lead delivery system formulation demonstrated exceptional stability over a one year period under a variety of conditions.

The DiLA2 formulation maintained in vivo knockdown activity with no observed loss in potency over the course of the year-long study when stored under conditions ranging from -80 oC to 4 oC.

In addition, neither change in particle characteristics such as size or charge nor loss in siRNA integrity was observed. The Company's proprietary UsiRNA constructs in the DiLA2 formulations have demonstrated superior activity for delivery to hepatocytes in rodent and non-human primates.

In addition, these compounds have demonstrated inhibition of mRNA via RNAi and subsequent reduction in tumor burden in the Company's oncology programs in liver and bladder cancer. Long-term stability of the DiLA2 formulation/UsiRNA cargo is an integral part of the development of the Company's drug products and represents further progress in these programs.

"The ability of our novel DiLA2 formulation to be stored frozen or at refrigerated conditions is unique," stated Barry Polisky, Ph.D., Chief Scientific Officer at MDRNA, Inc. "We have the flexibility to tailor storage conditions to meet the needs of our internal programs, pharma partners and ultimately the commercial requirements of a marketed RNAi-based therapeutic."

DiLA2 delivery platform is MDRNA's proprietary platform for creating novel liposomal delivery systems based on di-alkylated amino acids (DiLA2). The DiLA2 platform enables MDRNA to tailor the charge, linker length, and acyl chain characteristics to improve delivery of the liposomes to target tissue of interest.

In vivo studies have demonstrated effective delivery in models of metabolic disorders, cancer, and other diseases. DiLA2 based liposomes are well tolerated for repeat dose, and systemic and local administration. MDRNA is also utilizing condensing peptides to form peptide-siRNA nanoparticles to further increase the delivery efficiency of its DiLA2 delivery systems.
Advertisement